# Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

> **NCT00424242** · EARLY_PHASE1 · COMPLETED · sponsor: **Northwestern University** · enrollment: 15 (estimated)

## Conditions studied

- Brain and Central Nervous System Tumors
- Chronic Myeloproliferative Disorders
- Leukemia
- Lymphoma
- Lymphoproliferative Disorder
- Metastatic Cancer
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Precancerous Condition
- Secondary Myelofibrosis
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT00424242
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2010-01
- **Final completion:** 2011-09
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2021-09-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00424242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00424242, "Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00424242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*